{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:53:41Z","timestamp":1780415621846,"version":"3.54.1"},"reference-count":19,"publisher":"Japan Society for Clinical Immunology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2177\/jsci.39.30","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T22:07:05Z","timestamp":1463177225000},"page":"30-36","source":"Crossref","is-referenced-by-count":13,"title":["A review of adverse events caused by immune checkpoint inhibitors"],"prefix":"10.2177","volume":"39","author":[{"given":"Satoshi","family":"FUKUSHIMA","sequence":"first","affiliation":[{"name":"Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"972","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1) Hodi, F.S., et al.: Improved survival with ipilimumab in patients with metastatic melanoma. <i>N Engl J Med<\/i>. <b>363<\/b>, 711-723, 2010. doi: NEJMoa1003466 [pii] 10.1056\/NEJMoa1003466.","DOI":"10.1056\/NEJMoa1003466"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) Ribas, A.: Tumor immunotherapy directed at PD-1. <i>N Engl J Med<\/i>. <b>366<\/b>, 2517-2519, 2012. doi: 10.1056\/NEJMe1205943.","DOI":"10.1056\/NEJMe1205943"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Wolchok, J.D., et al.: Nivolumab plus ipilimumab in advanced melanoma. <i>N Engl J Med<\/i>. <b>369<\/b>, 122-133, 2013. doi: 10.1056\/NEJMoa1302369.","DOI":"10.1056\/NEJMoa1302369"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4) Schadendorf, D., et al.: Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>J Clin Oncol<\/i>. <b>33<\/b>, 1889-1894, 2015. doi:10.1200\/JCO.2014.56.2736.","DOI":"10.1200\/JCO.2014.56.2736"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Scott, L.J.: Nivolumab: A Review in Advanced Melanoma. <i>Drugs<\/i>. <b>75<\/b>, 1413-1424, 2015.doi: 10.1007\/s40265-015-0442-6.","DOI":"10.1007\/s40265-015-0442-6"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6) Horvat, T.Z., et al.: Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>J Clin Oncol<\/i>. <b>33<\/b>, 3193-3198, 2015. doi: 10.1200\/JCO.2015.60.8448.","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7) Weber, J., et al.: A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. <i>Clin Cancer Res<\/i>. <b>15<\/b>, 5591-5598, 2009. doi: 10.1158\/1078-0432.CCR-09-1024.","DOI":"10.1158\/1078-0432.CCR-09-1024"},{"key":"8","unstructured":"8) Villadolid, J., Amin, A.: Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. <i>Transl Lung Cancer Res<\/i>. <b>4<\/b>, 560-575, 2015. doi: 10.3978\/j.issn.2218-6751.2015.06.06."},{"key":"9","doi-asserted-by":"publisher","unstructured":"9) Robert, C., et al.: Nivolumab in previously untreated melanoma without BRAF mutation. <i>N Engl J Med<\/i>. <b>372<\/b>, 320-330, 2015. doi: 10.1056\/NEJMoa1412082.","DOI":"10.1056\/NEJMoa1412082"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10) Robert, C., et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. <i>N Engl J Med<\/i>. <b>364<\/b>, 2517-2526, 2011. doi: 10.1056\/NEJMoa1104621.","DOI":"10.1056\/NEJMoa1104621"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11) Robert, C., et al.: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet<\/i>. <b>384<\/b>, 1109-1117, 2014. doi: 10.1016\/S0140-6736(14)60958-2.","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12) Hamid, O., et al.: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. <i>N Engl J Med<\/i>. <b>369<\/b>, 134-144, 2013. doi: 10.1056\/NEJMoa1305133.","DOI":"10.1056\/NEJMoa1305133"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13) Weber, J.S., et al.: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncol<\/i>. <b>16<\/b>, 375-384, 2015. doi: 10.1016\/S1470-2045(15)70076-8.","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14) Rizvi, N.A., et al.: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncol<\/i>. <b>16<\/b>, 257-265, 2015. doi: 10.1016\/S1470-2045(15)70054-9.","DOI":"10.1016\/S1470-2045(15)70054-9"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15) Teulings, H.E., et al.: Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. <i>J Clin Oncol<\/i>. <b>33<\/b>, 773-781, 2015. doi: 10.1200\/JCO.2014.57.4756.","DOI":"10.1200\/JCO.2014.57.4756"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16) Yamazaki, N., et al.: Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. <i>Cancer Chemother Pharmacol<\/i>. <b>76<\/b>, 969-975, 2015. doi: 10.1007\/s00280-015-2870-0.","DOI":"10.1007\/s00280-015-2870-0"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17) Johnson, D.B., et al.: Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. <i>J Clin Oncol<\/i>. <b>33<\/b>, e122-124, 2015. doi: 10.1200\/JCO.2013.51.1683 (2015).","DOI":"10.1200\/JCO.2013.51.1683"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Shirai, T., et al.: Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. <i>Jpn J Clin Oncol<\/i>. <b>46<\/b>, 86-88, 2016. doi: 10.1093\/jjco\/hyv158.","DOI":"10.1093\/jjco\/hyv158"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Tanaka, M., Miyatake, T.: Anti-acetylcholine receptor antibody in aged individuals and in patients with Down&apos;s syndrome. <i>J Neuroimmunol<\/i>. <b>4<\/b>, 17-24, 1983.","DOI":"10.1016\/0165-5728(83)90060-7"}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u306b\u3088\u308b\u6709\u5bb3\u4e8b\u8c61"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/39\/1\/39_30\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T13:39:17Z","timestamp":1498311557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/39\/1\/39_30\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.39.30","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}